Skip to Main content Skip to Navigation
Master Thesis

Comparaison de la qualité de vie des franciliens à risque cardiovasculaire modéré et élevé selon la prise de statine en 2018

Abstract : Objectives: statins are treatments reducing cardiovascular disease and overall mortality in patients for the secondary and primary prevention. Although generally safe and well tolerated, statin therapy may cause myopathy, but long-term effects on health related quality of life (HRQoL) are unclear. We investigated whether statin use is associated with poorer HRQoL. Methods: this cross-sectional study enrolled all patients above 40 years old who were coming to laboratories across Île-de-France for a blood test to evaluate lipid profile. Patients, who didn’t need a statin therapy according to the recommendations of the European Society of Cardiology, were excluded. All patients in the study were asked to complete a selfadministered questionnaire to collect general data like cardiovascular risk factors, treatment adherence and socio-demographic characteristics. HRQoL was assessed using scores from the Medical Outcomes Survey 12 (SF-12): the Physical Component Score (PCS) and the Mental Component Score (MCS). Statin users were matched with non-statin on age, sex, educational level, smoking status, and whether they have an established cardiovascular disease, using a propensity score (ratio 1:1). Conditional logistical regression was used for analysis. Multiple linear regression models were used to evaluate factors associated with HRQoL in the overall population. Results: among 506 participants, 187 statin users where matched with 187 non-statin users. Statin users were on average 64.5 years old (+/- 9,6). Statin use wasn’t associated with HRQoL: (PCS (OR=0.978 [0.649 -1.475], p= 0.917) and MCS (OR= 0.776 [0.508 -1.185], p=0.24). In multivariate analysis, lower PCS and MCS scores were associated in secondary prevention especially those who had a stroke (respectively p=0.004 and p=0.006), low educational level (p=0.02) and family history of cardiovascular disease (p=0.04). MCS was also lower among female (p<0.001). Conclusion: statins use did not influence HRQoL. The results of this study could be used for shared decision making between practitioners and patients when statin therapy is discussed.
Document type :
Master Thesis
Complete list of metadata
Contributor : Université Paris Descartes - Scd Connect in order to contact the contributor
Submitted on : Tuesday, February 23, 2021 - 11:25:23 AM
Last modification on : Thursday, September 2, 2021 - 3:09:13 AM


Files produced by the author(s)


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License


  • HAL Id : dumas-03149654, version 1


Ouma-Cécilia Coumar. Comparaison de la qualité de vie des franciliens à risque cardiovasculaire modéré et élevé selon la prise de statine en 2018. Médecine humaine et pathologie. 2019. ⟨dumas-03149654⟩



Record views


Files downloads